Searched for
JAK INHIBITOR
Tata group’s Impetis out-licenses arthritis and autoimmune drugs to VyomeIn a significant move for medical innovation, Impetis Biosciences, a subsidiary of Tata group, has teamed up with Vyome Holdings from the U...- Mankind gets CDSCO nod for Phase 1 clinical trials for molecule to treat autoimmune disordersMankind Pharma has received CDSCO approval to begin Phase 1 clinical trials for MKP11093, a molecule targeting multiple autoimmune disorder...
- Sun Pharma’s baldness drug Leqselvi debuts in US market after patent dispute settledSun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for severe hair loss, ...
- Sun Pharma gets US FDA nod for its specialty drug against baldnessSun Pharma announced FDA approval of Leqselvi (deuruxolitinib) 8 mg tablets for severe alopecia areata, marking a major milestone after acq...
- Glenmark partners with Pfizer to launch abrocitinib in India to treat atopic dermatitisGlenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and CIBINQO. Developed by Pfizer, abrocitinib has rec...
- Sun Pharma subsidiary partners with Aclaris Therapeutics for licensing agreementAs per the pact, Aclaris grants Sun Pharma exclusive rights to specific patents for using deuruxolitinib, Sun Pharma's JAK inhibitor, or ot...
- Overactive inflammatory response could be at the root of long Covid: Studylooking at blood samples from 25 people who had had COVID but recovered, and from 25 volunteers who had never had COVID to their knowledge,...
- Cyndrella Carvalho on 6 pharma stocks to bet on nowValuations in the listed API space have experienced huge price corrections, making them appear attractive, according to Cyndrella Carvalho,...
- Sun Pharma to buy concert for $576 mConcert has pioneered the use of deuterium (a hydrogen isotope) in medicinal chemistry and has an extensive patent portfolio, including its...
- New study shows how blood cancer can progress, from chronic to aggressive, in someFor a small percentage, the slower-paced disease can transform into aggressive cancer.
- WHO 'strongly advises against' use of two COVID-19 antibody therapies, says British Medical JournalThe WHO Guideline Development Group of international experts noted that antibody drugs sotrovimab and casirivimab-imdevimab are not recomme...
- Eli Lilly receives permission to conduct Phase 3 clinical trials for Covid treatmentThe Subject Expert Committee (SEC) that advises the drug regulatory authority on new drugs, vaccines for Covid gave its permission to the c...
- New drugs that may cure baldness foundThe drugs inhibit a family of enzymes inside hair follicles that are suspended in a resting state, restoring hair growth.
Load More
